PharmaFocus: Vaccine Adjuvants in Infectious Disease

Summary

Originally discovered by Glenny in the 1920s, vaccine adjuvants have remained the pharmaceutical industry's “dirty little secret”. Today, vaccine adjuvants are credited with helping to bolster the immune response in the host post-vaccination. Recently, second-generation adjuvants have come under scrutiny after reports that the adjuvant used in certain pandemic influenza vaccines was linked to causing narcolepsy in Swedish and British adults. Such reports, compounded by the general mistrust of adjuvants, have resulted in these vital vaccine components becoming the scapegoat of the vaccine industry. However, immunologists and infectious disease specialists are in agreement over the beneficial uses of adjuvants in vaccines today, especially as a means to reduce the number of doses, increase the likelihood of a sustained immunological response and decrease the overall incidence of disease.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global vaccine adjuvant market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global vaccine adjuvant market in future.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Contents:

1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
3 Vaccines and the Host Immune Response
3.1 Vaccines in Infectious Disease
3.2 Host Immune Response
3.2.1 Primary Barriers Against Infection
3.2.2 Innate Immune System
3.2.3 Adaptive Immune System
3.3 Vaccine Adjuvants
3.3.1 Overview
3.3.2 Adjuvant Target: Dendritic Cells
3.3.3 Adjuvant Target: Toll-Like Receptors
3.3.4 Splenic Involvement in Immune Response
3.3.5 Antigen-Depot Effect
4 Market Drivers and Barriers
4.1 Overview
4.2 Drivers
4.2.1 Driver: Government initiatives to increase vaccination programs
4.2.2 Driver: New routes of administration for vaccines
4.2.3 Driver: Rapidly mutating pathogens
4.2.4 Driver: Recombinant vaccine technology
4.2.5 Driver: Increased research efforts against unvaccinated disease
4.3 Barriers
4.3.1 Barrier: Decreasing or stagnant vaccination rates
4.3.2 Barrier: Increasing vaccine prices
4.3.3 Barrier: Public opinion of vaccine and adjuvants
5 Current Adjuvant Options
5.1 Overview
5.2 Product Profiles – Major Adjuvant Classes
5.2.1 Aluminum Salts (Alum)
5.2.2 Emulsions
5.2.3 Particulate Delivery Mechanisms
5.2.4 Microbial Derivatives
5.2.5 Oligonucleotides
5.2.6 Adjuvant Systems
6 Needs Assessment and Opportunity Analysis
6.1 Overview
6.2 Unmet Needs Analysis
6.2.1 Adjuvant Safety
6.2.2 DC Recognition
6.2.3 Appropriate TLR Activation
6.2.4 Formulation and Dosing
6.3 Opportunity Analysis
6.3.1 Novel Routes of Administration and Splenic Involvement
6.3.2 Combinatorial Adjuvant Systems
6.3.3 Limited Use of Antigen Depot
7 Clinical Trials and Regulatory Strategy
7.1 Clinical Trial Design
7.1.1 Non-clinical Evaluation
7.1.2 Adjuvant Mechanism of Action Evaluation
7.1.3 Clinical Safety Evaluation
7.1.4 KOL Opinion on Clinical Design
7.2 Regulatory Strategy
7.2.1 Overview
7.2.2 World Health Organization (WHO)
7.2.3 US
7.2.4 EU
7.2.5 Cultural Differences in Adjuvant Use (US vs. Europe)
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Research Methodology
8.4 Physicians and Specialists Included in this Study
8.5 About the Authors
8.5.1 Author
8.5.2 Reviewer
8.5.3 Global Head of Healthcare
8.6 About Us
8.7 Contact Us
8.8 Disclaimer

1.1 List of Tables
Table 1: Primary Physical (Epithelial) Barriers to Infection
Table 2: Immune Cells and Their Corresponding Toll-like Receptors
Table 3: TLR Adjuvant Targets and Ligand Types in Clinical Trials for Infectious Disease Vaccines
Table 4: Vaccine Adjuvants – Drivers and Barriers, 2013
Table 5: Leading Adjuvants in Clinical Trials for Human Infectious Disease Vaccines
Table 6: Product Profile – Aluminum Salts/Alum
Table 7: Aluminum Salts/Alum SWOT Analysis, 2013
Table 8: Product Profile – Emulsions
Table 9: Emulsions SWOT Analysis, 2013
Table 10: Product Profile – Particulate Delivery Mechanisms
Table 11: Particulate Delivery Mechanisms SWOT Analysis, 2013
Table 12: Product Profile – Microbial Derivatives
Table 13: Microbial Derivatives SWOT Analysis, 2013
Table 14: Product Profile – Oligonucleotides
Table 15: Oligonucleotides SWOT Analysis, 2013
Table 16: Product Profile – Adjuvant Systems
Table 17: GSK's Adjuvant System Portfolio, 2013
Table 18: Adjuvant Systems SWOT Analysis, 2013
Table 19: Overall Unmet Needs – Current Level of Attainment
Table 20: Regulatory Guidelines for the Approval of Adjuvanted Vaccines

1.2 List of Figures
Figure 1: Immune System – Stimulation of Innate and Adaptive Responses
Figure 2: Adjuvant Targets – Human Toll-like Receptor Family
Figure 3: Adjuvant – Host Immune Response Interactions
Figure 4: Chemical Structure of MPL
Figure 5: Chemical Structure of Dinitrophenylated CpG ODN
Figure 6: WHO Map to Vaccine Adjuvant Usage

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2518955/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: PharmaFocus: Vaccine Adjuvants in Infectious Disease
Web Address: http://www.researchandmarkets.com/reports/2518955/
Office Code: SC6I5R2H

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>✔️</td>
<td>USD 3995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>✔️</td>
<td>USD 7990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprise Wide</td>
<td>☐</td>
<td>USD 11985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp